Currently, treatments for schizophrenia remain inadequate and precision medicine is often not used. For better identification and treatment we need to move toward better precision medicine and identify treatments that best meet needs of individual patients. Education can help relay gaps in care and summarize new data emerging on potential future treatment targets. This presentation will talk about a subgroup of people with schizophrenia that have higher inflammation and antibodies to gluten a protein in wheat, barley and rye. I will discuss possible treatment options in this group of people.